344 related articles for article (PubMed ID: 21847631)
1. Combination of targeted therapy and immunotherapy in melanoma.
Blank CU; Hooijkaas AI; Haanen JB; Schumacher TN
Cancer Immunol Immunother; 2011 Oct; 60(10):1359-71. PubMed ID: 21847631
[TBL] [Abstract][Full Text] [Related]
2. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapeutic approaches for the treatment of malignant melanoma.
Curiel-Lewandrowski C; Atkins MB
Curr Opin Investig Drugs; 2001 Nov; 2(11):1553-63. PubMed ID: 11763157
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
6. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of advanced or metastatic melanoma.
Cebon J; Gedye C; John T; Davis ID
Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
[TBL] [Abstract][Full Text] [Related]
8. Molecular markers of response to treatment for melanoma.
Sznol M
Cancer J; 2011; 17(2):127-33. PubMed ID: 21427556
[TBL] [Abstract][Full Text] [Related]
9. Treatment approaches for advanced cutaneous melanoma.
Stein JA; Brownell I
J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
[TBL] [Abstract][Full Text] [Related]
10. The treatment of melanoma with an emphasis on immunotherapeutic strategies.
Jack A; Boyes C; Aydin N; Alam K; Wallack M
Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and hurdles in melanoma immunotherapy.
Jandus C; Speiser D; Romero P
Pigment Cell Melanoma Res; 2009 Dec; 22(6):711-23. PubMed ID: 19735459
[TBL] [Abstract][Full Text] [Related]
12. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
Agarwala SS
Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial approach to treatment of melanoma.
Ashworth MT; Daud AI
Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
[TBL] [Abstract][Full Text] [Related]
14. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapeutic possibilities for treatment of malignant melanomas].
Kokoschka EM
Hautarzt; 1979 Dec; 30(12):656-61. PubMed ID: 317654
[TBL] [Abstract][Full Text] [Related]
16. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
17. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
18. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
[TBL] [Abstract][Full Text] [Related]
19. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
[TBL] [Abstract][Full Text] [Related]
20. Molecular-targeted therapy in malignant melanoma.
Sullivan RJ; Atkins MB
Expert Rev Anticancer Ther; 2009 May; 9(5):567-81. PubMed ID: 19445574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]